ELAN
Elanco Animal Health, Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.24
+2.60%Year over year
Reported trailing growth
- Revenue
- +12.0%
- EBITDA
- -49.3%
- EBIT
- +121.1%
- EPS
- —
- Free cash flow
- +6.8%
- Operating cash flow
- +7.9%
Forward estimates
Based on analyst estimates
- Revenue
- +6.7%
- EBITDA
- +101.5%
- EPS
- +395.6%
Three-year CAGR
- Revenue
- +2.2%
- EBITDA
- -7.9%
- EBIT
- -13.1%
- Net income
- —
- EPS
- —
- Free cash flow
- +2.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026